New guidelines for HER2 pathological diagnostics in gastric cancer.
New guidelines for HER2 pathological diagnostics in gastric cancer.
复制标题
胃癌 HER2 病理诊断新指南。
DOI：
10.1111/pin.12390
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Morii E.
中科院分区：
文献类型：
--
作者：
Wada R;Hirabayashi K;Ohike N;Morii E.
这篇社论的目的是介绍关于胃癌的人表皮生长因子受体 2 (HER2) 病理诊断的新指南，包括新的证据和数据。在乳腺癌中，HER2 蛋白过度表达和 HER2 基因扩增是重要的预后因素，也是治疗的目标。因此，已经制定了确定HER2过度表达的技术方法和标准。由于这些 HER2 发现在胃癌中也很重要，日本病理学会质量控制委员会制定了胃癌 HER2 表达的病理诊断指南，包括病理分析方法。这些指南由 Kijima Hiroshi 博士领导，于 2011 年 11 月发布（http://www.med.hirosaki-u.ac.jp/∼patho2/SeidoKanri/Igan_Her2.pdf）。本文建议的指南是根据新证据制定的，包括指南作者 Kijima 博士推荐的 Wada Ryo 博士、Hirabayashi Kenichi 博士和 Ohike Nobuyuki 博士的意见。还提出了新的数字。胃癌HER2病理诊断应参考本指南。
The aim of this editorial is to introduce new guidelines, including novel evidence and figures, on the human epidermal growth factor receptor 2 (HER2) pathological diagnosis of gastric cancer. In breast cancer, HER2 protein overexpression and HER2 gene amplification are significant prognostic factors and are targets for therapy. Therefore, technical methods and criteria for determining HER2 overexpression have been developed. Since these HER2 findings are also important in gastric cancer, the quality control committee of the Japanese Society of Pathology produced guidelines for the pathological diagnosis of HER2 expression in gastric cancer, including methods for pathological analysis. These guidelines were led by Dr. Kijima Hiroshi and were published in November 2011 (http://www. med. hirosaki-u. ac. jp/∼ patho2/SeidoKanri/Igan_Her2. pdf). The guidelines suggested in this paper were created based on new evidence and include inputs from Dr. Wada Ryo, Dr. Hirabayashi Kenichi, and Dr. Ohike Nobuyuki who were recommended by the guideline’s author, Dr. Kijima. New figures are also presented. These guidelines should be referred to for the pathological diagnosis of HER2 in gastric cancer.